Tarsus Reports Q1 Revenue of $162.05M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $162.05M, consensus $148.73M. "XDEMVY is driving a fundamental shift in how Demodex blepharitis is diagnosed and treated," said Bobak Azamian, Chief Executive Officer and Chairman of Tarsus. "As we look across the business, every key signal is gaining momentum, and we are seeing the market expand as a result - reinforcing XDEMVY's expected growth trajectory toward potential peak sales exceeding $2 billion. Equally as exciting, XDEMVY validates a repeatable playbook for category creation. We are now scaling that approach across our pipeline, with several catalysts ahead that we believe will drive the next phase of growth and establish new standards of care."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TARS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TARS
Wall Street analysts forecast TARS stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 57.410
Low
68.00
Averages
89.33
High
100.00
Current: 57.410
Low
68.00
Averages
89.33
High
100.00
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Achieve Life Sciences Appoints New Board Members Ahead of Cytisinicline Launch
- New Board Members: Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman to its Board of Directors, with Farrow bringing over $9 billion in acquisition experience in the biopharmaceutical sector and Waldman as the founder of Veradermics, both poised to provide strategic guidance for the upcoming NDA resubmission.
- Significant Market Potential: Farrow highlighted the large and underserved market for smoking dependence, with Cytisinicline expected to fill this gap as the first new prescription smoking cessation medication in nearly two decades, addressing the needs of approximately 25 million adult smokers in the U.S.
- Clinical Data Support: Waldman emphasized the encouraging results of Cytisinicline in clinical trials, particularly for e-cigarette cessation, indicating that the drug could become a new tool for nicotine dependence treatment, addressing the urgent needs of young patients and driving innovation in the biopharmaceutical field.
- Strategic Development Direction: Achieve Life Sciences' NDA application has received FDA Breakthrough Therapy designation, and with the extensive experience of the new board members, the company is advancing towards a successful launch of Cytisinicline, which is expected to create substantial value for both patients and shareholders.
See More
Tarsus Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Tarsus Pharmaceuticals plans to participate in the William Blair 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, showcasing its advancements in eye care and infectious disease prevention at 8:00 a.m. and 8:40 a.m. PT, respectively.
- Live Webcasts and Replays: The conferences will feature live webcasts accessible on Tarsus's website, with replays available within 48 hours, ensuring investors can stay updated on company developments and engage in discussions, thereby enhancing investor relations.
- Pipeline Progress: Tarsus's XDEMVY® (0.25% lotilaner ophthalmic solution) has received FDA approval for treating Demodex blepharitis, demonstrating the company's innovative capabilities in ophthalmology, while TP-04 and TP-05 are in development for ocular rosacea and Lyme disease prevention, respectively.
- Strategic Objectives: By participating in these conferences, Tarsus aims to not only showcase its treatment solutions in high unmet need areas but also attract more investor attention to its R&D progress, thereby driving long-term growth for the company.
See More
John Cena Partners with Tarsus to Raise Awareness of Eyelid Disease
- Awareness Campaign: Tarsus Pharmaceuticals has partnered with John Cena to raise awareness about Demodex blepharitis, a common eyelid disease, with Cena's personal experience aimed at helping millions recognize the significance of this condition.
- Symptoms and Treatment: Cena shared his years of suffering from eyelid redness, itching, and crusting, introducing FDA-approved XDEMVY® (lotilaner ophthalmic solution) as the only treatment targeting Demodex blepharitis, emphasizing the importance of seeking timely medical care.
- Patient Education: Tarsus CEO Bobby Azamian noted that Cena's relatable story encourages people to prioritize eye health and undergo regular eye exams to detect and treat underlying conditions early.
- Market Potential: The Titan study indicates that as many as 25 million Americans may be affected by Demodex blepharitis, and Tarsus aims to enhance public awareness through this campaign, potentially increasing the market acceptance of XDEMVY.
See More
Tarsus Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Sales Growth: In Q1 2026, Tarsus Pharmaceuticals reported over $145 million in net product sales for XDEMVY, reflecting an 85% year-over-year increase, indicating strong market acceptance and physician endorsement, which is expected to drive growth in the coming years.
- Full-Year Guidance Reaffirmed: Management reiterated its full-year 2026 guidance of net product sales between $670 million and $700 million, with gross margins around 93%, demonstrating confidence in future performance and reflecting a solid position in market competition.
- New Product Development Progress: Tarsus has initiated a Phase II trial for TP-05 with approximately 700 participants aimed at preventing Lyme disease, with top-line data expected in the first half of 2027, which will provide crucial support for the company's future product line expansion.
- One-Time Milestone Revenue: The company reported $16.7 million in license fees and collaboration revenues for the quarter, including a one-time $15 million regulatory milestone from the approval of TP-03 in Greater China, which will provide additional financial support for the company.
See More
Tarsus (TARS) Q1 2026 Earnings Transcript
See More
Tarsus Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Release Date: Tarsus Pharmaceuticals is set to announce its Q1 earnings on May 6th after market close, with a consensus EPS estimate of -$0.40, reflecting a 37.5% year-over-year improvement, indicating potential financial performance enhancement.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $148.73 million, representing an impressive 89.9% year-over-year increase, which underscores the company's strong growth in market demand and product sales, potentially laying the groundwork for future profitability.
- Estimate Revision Dynamics: Over the past three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a cautious stance from analysts regarding the company's short-term performance, which may affect investor confidence.
- Future Sales Outlook: Tarsus expects sales to reach between $670 million and $700 million by 2026, with XDEMVY poised to become a blockbuster product exceeding $2 billion, highlighting the company's positive prospects in pipeline advancement and market potential.
See More
Achieve Life Sciences Appoints New Board Members Ahead of Cytisinicline Launch
- New Board Members: Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman to its Board of Directors, with Farrow bringing over $9 billion in acquisition experience in the biopharmaceutical sector and Waldman as the founder of Veradermics, both poised to provide strategic guidance for the upcoming NDA resubmission.
- Significant Market Potential: Farrow highlighted the large and underserved market for smoking dependence, with Cytisinicline expected to fill this gap as the first new prescription smoking cessation medication in nearly two decades, addressing the needs of approximately 25 million adult smokers in the U.S.
- Clinical Data Support: Waldman emphasized the encouraging results of Cytisinicline in clinical trials, particularly for e-cigarette cessation, indicating that the drug could become a new tool for nicotine dependence treatment, addressing the urgent needs of young patients and driving innovation in the biopharmaceutical field.
- Strategic Development Direction: Achieve Life Sciences' NDA application has received FDA Breakthrough Therapy designation, and with the extensive experience of the new board members, the company is advancing towards a successful launch of Cytisinicline, which is expected to create substantial value for both patients and shareholders.
See More
Tarsus Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Tarsus Pharmaceuticals plans to participate in the William Blair 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, showcasing its advancements in eye care and infectious disease prevention at 8:00 a.m. and 8:40 a.m. PT, respectively.
- Live Webcasts and Replays: The conferences will feature live webcasts accessible on Tarsus's website, with replays available within 48 hours, ensuring investors can stay updated on company developments and engage in discussions, thereby enhancing investor relations.
- Pipeline Progress: Tarsus's XDEMVY® (0.25% lotilaner ophthalmic solution) has received FDA approval for treating Demodex blepharitis, demonstrating the company's innovative capabilities in ophthalmology, while TP-04 and TP-05 are in development for ocular rosacea and Lyme disease prevention, respectively.
- Strategic Objectives: By participating in these conferences, Tarsus aims to not only showcase its treatment solutions in high unmet need areas but also attract more investor attention to its R&D progress, thereby driving long-term growth for the company.
See More
John Cena Partners with Tarsus to Raise Awareness of Eyelid Disease
- Awareness Campaign: Tarsus Pharmaceuticals has partnered with John Cena to raise awareness about Demodex blepharitis, a common eyelid disease, with Cena's personal experience aimed at helping millions recognize the significance of this condition.
- Symptoms and Treatment: Cena shared his years of suffering from eyelid redness, itching, and crusting, introducing FDA-approved XDEMVY® (lotilaner ophthalmic solution) as the only treatment targeting Demodex blepharitis, emphasizing the importance of seeking timely medical care.
- Patient Education: Tarsus CEO Bobby Azamian noted that Cena's relatable story encourages people to prioritize eye health and undergo regular eye exams to detect and treat underlying conditions early.
- Market Potential: The Titan study indicates that as many as 25 million Americans may be affected by Demodex blepharitis, and Tarsus aims to enhance public awareness through this campaign, potentially increasing the market acceptance of XDEMVY.
See More
Tarsus Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Sales Growth: In Q1 2026, Tarsus Pharmaceuticals reported over $145 million in net product sales for XDEMVY, reflecting an 85% year-over-year increase, indicating strong market acceptance and physician endorsement, which is expected to drive growth in the coming years.
- Full-Year Guidance Reaffirmed: Management reiterated its full-year 2026 guidance of net product sales between $670 million and $700 million, with gross margins around 93%, demonstrating confidence in future performance and reflecting a solid position in market competition.
- New Product Development Progress: Tarsus has initiated a Phase II trial for TP-05 with approximately 700 participants aimed at preventing Lyme disease, with top-line data expected in the first half of 2027, which will provide crucial support for the company's future product line expansion.
- One-Time Milestone Revenue: The company reported $16.7 million in license fees and collaboration revenues for the quarter, including a one-time $15 million regulatory milestone from the approval of TP-03 in Greater China, which will provide additional financial support for the company.
See More
Tarsus (TARS) Q1 2026 Earnings Transcript
See More
Tarsus Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Release Date: Tarsus Pharmaceuticals is set to announce its Q1 earnings on May 6th after market close, with a consensus EPS estimate of -$0.40, reflecting a 37.5% year-over-year improvement, indicating potential financial performance enhancement.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $148.73 million, representing an impressive 89.9% year-over-year increase, which underscores the company's strong growth in market demand and product sales, potentially laying the groundwork for future profitability.
- Estimate Revision Dynamics: Over the past three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a cautious stance from analysts regarding the company's short-term performance, which may affect investor confidence.
- Future Sales Outlook: Tarsus expects sales to reach between $670 million and $700 million by 2026, with XDEMVY poised to become a blockbuster product exceeding $2 billion, highlighting the company's positive prospects in pipeline advancement and market potential.
See More
